{"name":"Azienda Ospedaliero Universitaria di Sassari","slug":"azienda-ospedaliero-universitaria-di-sassari","ticker":"","exchange":"","domain":"","description":"Azienda Ospedaliero Universitaria di Sassari is a university hospital in Italy that focuses on clinical care, research, and education. It has a growing presence in the pharmaceutical sector with a focus on developing and marketing drugs in cardiovascular health.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Ticagrelor standard tablets","genericName":"Ticagrelor standard tablets","slug":"ticagrelor-standard-tablets","indication":"Acute coronary syndrome (ACS) including ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI)","status":"phase_3"},{"name":"Ticagrelor orodispersible tablets","genericName":"Ticagrelor orodispersible tablets","slug":"ticagrelor-orodispersible-tablets","indication":"Acute coronary syndrome (ACS) for prevention of thrombotic cardiovascular events","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"EZE/simvastatin","genericName":"EZE/simvastatin","slug":"eze-simvastatin","indication":"Hypercholesterolemia and mixed dyslipidemia","status":"marketed"}]}],"pipeline":[{"name":"Ticagrelor standard tablets","genericName":"Ticagrelor standard tablets","slug":"ticagrelor-standard-tablets","phase":"phase_3","mechanism":"Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events.","indications":["Acute coronary syndrome (ACS) including ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI)","Secondary prevention of atherothrombotic events in patients with a history of myocardial infarction"],"catalyst":""},{"name":"EZE/simvastatin","genericName":"EZE/simvastatin","slug":"eze-simvastatin","phase":"marketed","mechanism":"EZE/simvastatin combines ezetimibe (which blocks cholesterol absorption in the intestine) with simvastatin (which inhibits HMG-CoA reductase to reduce cholesterol synthesis) for dual lipid-lowering action.","indications":["Hypercholesterolemia and mixed dyslipidemia"],"catalyst":""},{"name":"Ticagrelor orodispersible tablets","genericName":"Ticagrelor orodispersible tablets","slug":"ticagrelor-orodispersible-tablets","phase":"phase_3","mechanism":"Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events.","indications":["Acute coronary syndrome (ACS) for prevention of thrombotic cardiovascular events","Secondary prevention of atherothrombotic events in patients with prior myocardial infarction"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}